Sort by
Biochemistry, Genetics and Molecular Biology
Genome Instability
100%
Macrophage
100%
Chromosome Instability
100%
PD-L1
100%
Overall Survival
100%
Transcriptomics
100%
Cyclin E
100%
B Cell
100%
Trastuzumab
100%
Genomics
100%
Targeted Therapy
100%
Keyphrases
Molecular Landscape
100%
CCNE1
100%
CCNE1 Amplification
100%
Esophagogastric Cancer
100%
Gastric Cancer
50%
Molecular Profile
25%
Profile Analysis
12%
Molecular Analysis
12%
Lymph Node
12%
Tumor
12%
Liver
12%
Integrated Genomics
12%
Targeted Therapy
12%
Overexpression
12%
B Cells
12%
Genomic Instability
12%
Trastuzumab
12%
Treatment Outcome
12%
Genomic Profiling
12%
Predictive Biomarker
12%
Primary Tumor
12%
Advanced Gastric Cancer
12%
TP53 mutation
12%
Chromosomal Instability
12%
Tumor mutational Burden
12%
Transcriptomic Profiling
12%
Response to Therapy
12%
Molecular Subtypes
12%
Clinical Significance
12%
Cyclin E
12%
Survival Analysis
12%
Impact Response
12%
5-year Survival
12%
M1 Macrophages
12%
Critical Drivers
12%
Transcriptional Analysis
12%
PD-L1 Expression
12%
Molecular Features
12%
Cancer Types
12%
Immune Profile
12%
Esophageal Adenocarcinoma
12%
Immune Markers
12%
Therapeutic Implications
12%
Esophageal Squamous Cell Carcinoma
12%
Gastric Adenocarcinoma
12%
Metastatic Site
12%
ERBB2 Amplification
12%
Molecular Treatment
12%
CDH1 mutation
12%
Immune Profiling
12%
Gastric Cancer Biomarker
12%
Oesophagogastric Tumours
12%
Esophagogastric Junction Carcinoma
12%
HER2-positive Tumors
12%
Immunology and Microbiology
Immunotherapy
100%
Macrophage
50%
B Cell
50%
Programmed Death-Ligand 1
50%
Trastuzumab
50%
Transcriptomics
50%
Squamous Cell
50%
Chromosomal Instability
50%
Cyclin E
50%
Overall Survival
50%
Genomic Instability
50%
Lymph Node
50%
Tumor Mutational Burden
50%
Medicine and Dentistry
Malignant Neoplasm
100%
Abdominal Cancer
100%
Biological Marker
50%
Tumor
50%
Immunotherapy
33%
B Cell
16%
Targeted Therapy
16%
Programmed Death-Ligand 1
16%
Carcinoma
16%
Survival Analysis
16%
Primary Tumor
16%
Chromosomal Instability
16%
Macrophage
16%
Lymph Node
16%
Transcriptomics
16%
Cyclin E
16%
Overall Survival
16%
Genomic Instability
16%
Cancer Types
16%
Esophageal Adenocarcinoma
16%
Stomach Adenocarcinoma
16%
Esophageal Squamous Cell Carcinoma
16%
Trastuzumab
16%
Tumor Mutational Burden
16%
Treatment Outcome
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Abdominal Cancer
100%
Biological Marker
50%
Immunotherapy
33%
Overall Survival
16%
Cyclin E
16%
Esophageal Squamous Cell Carcinoma
16%
Chromosomal Instability
16%
Esophageal Adenocarcinoma
16%
Stomach Adenocarcinoma
16%
Neoplasm
16%
Primary Tumor
16%
Carcinoma
16%
Trastuzumab
16%